Dr. Gilmore O’Neill is the current CEO of Editas Medicine, having taken on the role in June 2022. He holds a Ph.D. in Biomedical Engineering from the University of California, San Diego, which lays a solid foundation for his work...
Dr. Gilmore O’Neill is the current CEO of Editas Medicine, having taken on the role in June 2022. He holds a Ph.D. in Biomedical Engineering from the University of California, San Diego, which lays a solid foundation for his work in the biotechnology sector. O’Neill previously held significant positions at Sarepta Therapeutics and Biogen, indicating that he has been active in the biopharma landscape for a long time. His leadership approach is closely linked to performance, as his recent compensation reflects increasing company goals, including an impressive annual bonus that rewards achieving corporate objectives. In 2023, he earned a total compensation of approximately $2.4 million, largely from performance-based stock units that vest based on reaching crucial research and development milestones. This aligns his interests with those of the shareholders, showcasing a results-driven philosophy. His current stock portfolio also highlights a commitment to the company's success, as he holds a significant number of shares. O’Neill is not just a figurehead; he embodies the biotech spirit of innovation and strategic growth. Under his guidance, Editas is positioned to impact genetic medicine and gene editing, matching the excitement of a rapidly evolving field.